Retire from ONE Stock?! [Ticker Symbol Revealed]
Jeff Clark has used one stock -- just one -- to show his readers gains of 85% in 14 days, 176% in 5 weeks, 41% in two weeks, 120% in 3 months, 138% in 8 days, 186% in 8 days, 222% in 8 days, and many more... With gains like that, is it really possible to retire from this ONE stock alone?
Financials
| Curr Year EPS Estimate | -0.18 |
| Next Quarter EPS Estimate | -0.88 |
| Profit Margin | -15.86% |
| Operating Margin | -8.98 |
| Return on Assets | -0.03 |
| Return on Equity | -15.01 |
| Revenue | 2.1B |
| Earnings Per Share | -2.63 |
| Revenue Per Share | 16.52 |
| Gross Profit | 1,788,384,000 |
| Quarterly Revenue Growth | -0.33 |
General
| Name | Alnylam Pharmaceuticals Inc |
| Ticker | ALNY |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Currency | USD |
| Country | USA |
| Fiscal Year End | December |
| Full Time Employees | 2,100 |
About Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Earnings
FireAid, with Billie Eilish and Lady Gaga, is the latest in a long line of massive benefit concerts
Billie Eilish, Sting, Red Hot Chili Peppers and others in a efforts, is the latest event to combine music and philanthropy.
Polymarket Bets Turn Bullish On 2025 Dogecoin ETF After Bitwise Move
Bets favoring approval of a Dogecoin (CRYPTO: DOGE) exchange-traded fund in 2025 surged on Polymarket after cryptocurrency fund manager Bitwise Asset Management formally applied with the SEC.
January 28th: Gold SHOCK? - Ad
On January 28th, an event is taking place that could completely shock the market. Stocks could go ballistic... Businesses could get blindsided... The gold market could get rocked... And one man, millionaire trader Jeff Clark is pounding the table on one single stock before this event.
Dan Ives Expects Meta And Microsoft To Stand Firm On $60 - $80 Billion AI Spending Plans Amid DeepSeek's Disruptive AI Model
Wedbush Securities analyst Dan Ives expects Meta Platforms Inc. and Microsoft Corp. to stand firm on their ambitious artificial intelligence spending plans during their upcoming earnings calls, despite recent market jitters over Chinese AI startup DeepSeek's emergence.
Stock market today: Asian stocks advance ahead of the Fed's rate decision as panic over AI fades
HONG KONG (AP) — Asian stocks advanced Wednesday in thin Lunar New Year trading following a rebound on Wall Street driven by tech stocks as the panic over Chinese AI company DeepSeek faded.
The No. 1 Stock for Trump's Second Term? - Ad
Legendary investor Louis Navellier's stock rating system gave a buy rating to ALL of the top 30 performing stocks in the S&P 500 index of Trump's first term... ALL of them! His system is now rating these stocks as a "BUY" for Trump's second term.
Magnificent 7 Earnings Ahead: 3 ETFs To Ride The Wave
Earnings season in full swing, attention on tech giants known as Magnificent 7: 3 ETFs to consider.
F5 Sees Big Wins in Multi-Cloud, AI Security, and IT Refresh, Analysts Forecast More Upside
F5 Inc (NASDAQ: FFIV) reported strong Q1 results, beating revenue and EPS estimates. The stock gained as analysts raised price targets and expectations for further growth from IT budgets, data center refresh, and AI demand.
He Called Bitcoin to $100k... Now He Says This Coin Is Next - Ad
Juan Villaverde may be America's top crypto expert. According to Juan's timing model, we are entering what could be the biggest bull market in crypto's history. With America's first crypto president in office, it could be the biggest gains the market has ever seen. And one special coin could skyrocket.
Did DeepSeek copy ChatGPT? Trump adviser thinks so
Did the upstart copy ChatGPT to make the artificial intelligence technology that this week?
What's Going On With Manhattan Associates Shares Wednesday?
Manhattan Associates shares are trading lower on Wednesday after the company announced soft guidance for the 2025 fiscal-year.
My TOP Altcoin for Right Now Is... - Ad
Searching for the top investment opportunity in crypto? Look no further. Our $3 report gives you the full scoop. You'll get this exciting token's name, our recommended investment strategy, and growth projections. Time is of the essence with this one...
AI-assisted works can get copyright with enough human creativity, says US copyright office
Artists can copyright works they made with the help of artificial intelligence, according to a new report by the U.S. Copyright Office that could help clear the way for the use of AI tools in Hollywood, the music industry and other creative fields.
Wall Street's Most Accurate Analysts Weigh In On 3 Consumer Stocks With Over 5% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks.
The Disaster Recovery Leader - Ad
From $15M+ contracts to booming scrap demand, this company is dominating a $42B market.
Shipments of uranium ore can resume under agreement reached with the Navajo Nation
Shipments of uranium ore from just south of the Grand Canyon are expected to resume in February after the Navajo Nation reached a settlement with the mining company, clearing the way for trucks to transport the ore across the largest Native American reservation in the U.S.
6 Clean Energy Stocks Face Challenges, Opportunities Ahead Of Earnings
Analyst revises ratings/price forecast on clean energy stocks ahead of earnings release. Highlights key areas to watch for each company.
Crypto Stocks Surge Amid Market Boom - Ad
Crypto stocks are on fire as Bitcoin hits all-time highs. One under-the-radar company is leading the charge, managing $2.1 billion in client assets and seeing record trading volumes. With crypto adoption skyrocketing, this could be a game-changing opportunity.
Ozempic Receives FDA Approval To Treat Kidney Disease
The FDA on Tuesday approves Ozempic, the weight loss drug made by Novo Nordisk, for the treatment of chronic kidney disease in patients who also have type 2 diabetes.
UK Faces Triple Threat as Economic Uncertainty Hits
The United Kingdom faces a decline in stock market listings, demographic crisis, and diminishing tax revenue with an exodus of high earners.
Ex CIA Predicts 40% "Double Crash" -- April 11 - Ad
I strongly advise taking action ahead of this NEW kind of economic crash... What makes this new crash so uniquely dangerous is that it could erase bank accounts.... My best followers are already following the steps laid out in this video. Prepare now, or suffer when the market implodes by 40% in a single day as soon as April 11. You've been warned.
7 AI Infrastructure Stocks Plunge Over 20%, Outpace Semiconductor Rout As DeepSeek Upends Investment Landscape
The launch of DeepSeek affects the AI boom including the power, cooling and data center giants that once rode the AI euphoria, which now have single-day losses exceeding 20%.
Nvidia Says DeepSeek An 'Illustration' Of How New AI Models Can Be Created While Being Export-Control Compliant Amid $600 Billion Market Value Plunge
Nvidia Corp. has thrown its support behind China's DeepSeek R1 artificial intelligence model, calling it "an excellent AI advancement" even as the startup's emergence triggered a historic $600 billion plunge in the chipmaker's market value on Monday.
Unlocking a Polymetallic Discovery Like No Other - Ad
With drill results rivaling the best in the world and a fully funded 2025 program, this polymetallic stock is poised for major growth. Industry icons Robert Friedland and Rob McEwen are already in. Will you be next?
Trump White House Puts DeepSeek Under National Security Scanner: 'Wake-Up Call To The American AI Industry'
The White House is reviewing China's DeepSeek AI for potential national security risks, amid growing concerns over intellectual property theft and its impact on U.S. AI dominance.
Microsoft reports 10% quarterly profit growth as it works to show AI investments paying off
REDMOND, Wash. (AP) — Microsoft Corp. said Wednesday that its profit for the October-December quarter grew 10% from the same time last year as it works to capitalize on the huge amounts of money it has spent to advance its artificial intelligence technology.
Top-Secret Military Base in New Mexico Desert - Ad
Out in the New Mexico desert sits a top secret government facility... The scientists here are studying a new technology that will change the way wars are fought... Once you see this thing for yourself -- you'll know in your heart it could be coming for all of us. That's why I've taken steps to help protect myself and my family from what could be unleashed as early as April 11.
Cathie Wood Dumps Tesla Stock Ahead Of Q4 Earnings, Ark Invest Loads Up On Amazon
On Tuesday, Jan. 28, 2025 Cathie Wood-led Ark Invest sold shares of Tesla ahead of its fourth-quarter earnings. Wood purchased Amazon shares on the same day.
Sysco's Sales Perform Well, But Case Growth Concerns Weigh On Stock, Say Analysts
Sysco Corp's second-quarter earnings showed slight misses in adjusted EBITDA, totaling $969 million, and a minor decline in case growth for US Foodservice. Despite challenges, a lower tax rate contributed to EPS of $0.93.
The Stock Rebuilding America - Ad
Wildfires and hurricanes wreaked havoc, but one company is turning debris into dollars.
Jeff Bezos-Backed Perplexity Revises TikTok Merger Deal, Proposes Giving US Government 50% Stake: Report
Jeff Bezos-backed Perplexity AI has proposed merging with TikTok's U.S. operations, offering the U.S. government a 50% stake via a $300 billion IPO while allowing ByteDance to retain ties without the proprietary recommendation algorithm.
A South Florida luxury condo project is planned for site where building collapse killed 98 people
SURFSIDE, Fla. (AP) — A Dubai-based developer plans to build a 12-story luxury condominium project on the South Florida site where in 2021, killing 98 people.
The $20 Stock Powering NVIDIA, TESLA, and Microsoft - Ad
The biggest AI firms in the world... All rely on this single company. And right now, you can get in for only $20 - but not for long.
Nvidia Stock Slides Overnight On Robinhood As China's DeepSeek Sparks Doubts Over GPU Spending Frenzy — Chamath Palihapitiya Highlights Report Indicating AI Holy Grail Cracked
Nvidia shares fell 3.12% after China's DeepSeek unveiled an AI model that delivers cutting-edge performance at a fraction of the cost, raising concerns over the necessity of massive GPU-related spending.
Edmunds' hybrid SUV test: 2025 Hyundai Tucson Hybrid vs 2025 Toyota RAV4 Hybrid
Hybrids are hot right now, and you have lots of choices if you’re considering a hybrid SUV. For years, the Toyota RAV4 Hybrid has been the go-to model for hybrid SUV shoppers.
Elon Musk: "AI Will Run Out of Electricity ... in 2025" - Ad
This AI boom is going to push America's power grid to the brink... Elon Musk even recently said that AI could run out of electricity by 2025. This crisis may just reveal one of the greatest investment ideas we are ever going to find. My research has recently uncovered two companies that could make a massive difference today.
Czech Central Bank Considering 5% Bitcoin Reserve
The Czech National Bank (CNB) could become the first Western central bank known to allocate a portion of its reserves to Bitcoin (CRYPTO: BTC).
Fed Set To Signal No Rush To Cut Rates As Wall Street Awaits Policy Clarity
Fed expected to keep rates steady, but Wall Street desperate for clarity on when next cut will come. Markets hoping for a dovish signal, but Powell may not deliver. Odds of two cuts in 2025 at 93%, with $4 payout for single cut and $6 for no cuts.
Crypto Stocks Surge Amid Market Boom - Ad
Crypto stocks are on fire as Bitcoin hits all-time highs. One under-the-radar company is leading the charge, managing $2.1 billion in client assets and seeing record trading volumes. With crypto adoption skyrocketing, this could be a game-changing opportunity.
SoFi Stock Falls On Soft Guidance Despite 'Strong Quarter' With Record Member Growth, Loan Originations: Analyst
SoFi reported better-than-expected Q4 financial results on Monday. But fiscal 2025 profit guidance dragged the stock down on Monday.
Information, charts or examples are for illustration and educational purposes only and not for individualized investment management This message contains commercial elements, such as advertising. We only send these offers to those who have opted in to our newsletter. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault.